<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041626</url>
  </required_header>
  <id_info>
    <org_study_id>T302</org_study_id>
    <nct_id>NCT00041626</nct_id>
    <nct_alias>NCT00040716</nct_alias>
  </id_info>
  <brief_title>Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Introgen Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Introgen Therapeutics</source>
  <brief_summary>
    <textblock>
      There is a need for more treatment options for patients with recurrent squamous cell cancer
      of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that
      include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the
      development of tumors. In this study the transfer of the p53 gene to tumor cells using a
      modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil)
      will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed
      surgery and radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Carcinoma, Squamous Cell</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>INGN 201</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  18 years or older

          -  Must have had radiation treatment

          -  Eligible for chemotherapy

          -  Not eligible for surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Menander, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Julie L Sicam, MT (ASCP) MSHS</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_contact>
    <last_name>Introgen Therapeutics, Inc.</last_name>
    <phone>866.631.4646</phone>
    <email>clinicaltrials@introgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Duvall</last_name>
      <phone>501-526-7129</phone>
      <email>kaduvall@uams.edu</email>
    </contact>
    <investigator>
      <last_name>James Suen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unversity of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Hines</last_name>
      <phone>720-848-0678</phone>
      <email>Brittany.Hines@uchsc.edu</email>
    </contact>
    <investigator>
      <last_name>Madeleine Kane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gachupin-Garcia</last_name>
      <phone>305-243-3379</phone>
      <email>agachupin@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jarrad Goodwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Neamtu</last_name>
      <phone>502-629-4679</phone>
      <email>daniela.neamtu@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>John Hamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Center of GBMC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Titus</last_name>
      <phone>443-849-3285</phone>
      <email>ltitus@gbmc.org</email>
    </contact>
    <investigator>
      <last_name>Marshall Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WJB Dorn VA Medical Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Reynolds</last_name>
      <phone>803-776-4000</phone>
      <phone_ext>6074</phone_ext>
      <email>Justin.Reynolds@va.gov</email>
    </contact>
    <investigator>
      <last_name>William Hrushesky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlen Waclawczyk</last_name>
      <phone>214-658-1985</phone>
      <email>awaclawczyk@mcmrc.com</email>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Andersen Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aida Berryman</last_name>
      <phone>713-745-1428</phone>
      <email>atberryman@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Gary Clayman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2002</study_first_submitted>
  <study_first_submitted_qc>July 11, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2002</study_first_posted>
  <last_update_submitted>September 10, 2007</last_update_submitted>
  <last_update_submitted_qc>September 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2007</last_update_posted>
  <keyword>Recurrent Squamous Cell Carcinoma of the Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

